Filtered By:
Specialty: Cardiology
Drug: Zetia

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 100 results found since Jan 2013.

Lipid-Modifying Therapies and Stroke Prevention
Curr Neurol Neurosci Rep. 2022 May 13. doi: 10.1007/s11910-022-01197-4. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: We reviewed lipid-modifying therapies and the risk of stroke and other cerebrovascular outcomes, with a focus on newer therapies.RECENT FINDINGS: Statins and ezetimibe reduce ischemic stroke risk without increasing hemorrhagic stroke risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors similarly reduce ischemic stroke risk in statin-treated patients with atherosclerosis without increasing hemorrhagic stroke, even with very low achieved low-density lipoprotein cholesterol levels. Icosape...
Source: Atherosclerosis - May 13, 2022 Category: Cardiology Authors: Daniel G Hackam Robert A Hegele Source Type: research

Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials
CONCLUSIONS AND RELEVANCE: This study suggests that the benefits and risks of more intensive LDL-C-lowering statin-based therapies for recurrent stroke risk reduction might be more favorable than the benefits and risks of less intensive LDL-C-lowering statin-based therapies, especially for patients with evidence of atherosclerosis.PMID:35188949 | DOI:10.1001/jamaneurol.2021.5578
Source: Atherosclerosis - February 21, 2022 Category: Cardiology Authors: Meng Lee Chun-Yu Cheng Yi-Ling Wu Jiann-Der Lee Chia-Yu Hsu Bruce Ovbiagele Source Type: research

Intracranial Hemorrhage in the TST Trial
CONCLUSIONS: Targeting an LDL cholesterol of <70 mg/dL compared with 100±10 mg/dL in patients with atherosclerotic ischemic stroke nonsignificantly increased the risk of ICH. Incident ICHs were not associated with low LDL cholesterol. Uncontrolled hypertension and anticoagulant therapy were associated with ICH which has important clinical implications.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01252875; EUDRACT identifier: 2009-A01280-57.PMID:34963300 | DOI:10.1161/STROKEAHA.121.035846
Source: Atherosclerosis - December 29, 2021 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Philippa C Lavall ée Byung-Chul Lee Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research

Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany
Abstract: Little recent data are available about the patterns of prescription for fibrates in patients followed in primary care practices. Therefore, the goal of this study was to analyze the prevalence of and the factors associated with the use of fibrates among patients receiving lipid-lowering drugs in Germany. The study included patients aged ≥18 years with at least 1 visit to 1 of 1070 general practices in Germany between January and December 2019. Lipid-lowering drugs included statins (without and with ezetimibe) and fibrates. The prevalence of the prescription of fibrates corresponded to the number of patients...
Source: Journal of Cardiovascular Pharmacology - December 1, 2021 Category: Cardiology Tags: Original Article Source Type: research

The Projected Impact of Population-Wide Achievement of LDL Cholesterol & lt;70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD
ConclusionA substantial number of recurrent ASCVD events could be averted over 10 years if all US adults with ASCVD achieved, and maintained, an LDL-C<70 mg/dL.
Source: Cardiovascular Drugs and Therapy - October 2, 2021 Category: Cardiology Source Type: research

Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study
ConclusionsPatients undergoing a coronary revascularization procedure who received moderate-intensity statins plus ezetimibe showed similar rates of major adverse cardiovascular events as patients who received high-intensity statins.
Source: Cardiovascular Drugs and Therapy - September 17, 2021 Category: Cardiology Source Type: research

A  Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
AbstractPatients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the goal of lowering the Lp(a) level in patients who have increased risk. The American College of Cardiology (ACC) has provided guidelines on how to use traditional lipid profiles to assess the risk of atherosclerotic cardiovascular disease (ASCVD); however, even with the emergence of statin add-on therapies such as ezetimibe and proprotein convert...
Source: American Journal of Cardiovascular Drugs - September 7, 2021 Category: Cardiology Source Type: research

Searching for the ideal LDL cholesterol estimating formula
For long, low-density lipoprotein cholesterol (LDL-C) has been considered one of the major therapeutic targets for primary and secondary prevention in cardiovascular (CV) disease. Since more than two decades ago, pivotal trials have demonstrated that LDL-C lowering with statins translates into a log proportional reduction in a vast array of CV events (myocardial infarction, stroke, need for coronary or arterial revascularization), as well as mortality [1]. More recently, similar benefits have been observed with other LDL-C lowering therapies, such as ezetimibe [2] and proprotein covertase subtilisin kexin type 9 (PCSK-9) inhibitors [3].
Source: International Journal of Cardiology - March 9, 2021 Category: Cardiology Authors: Remo Holanda de Mendonca Furtado Tags: Editorial Source Type: research

Carotid Atherosclerosis Evolution when Targeting a Low-Density Lipoprotein Cholesterol Concentration < 70 mg/dL after an Ischemic Stroke of Atherosclerotic Origin.
Conclusions: In patients with ischemic stroke and atherosclerosis, an LDL-C target of <70 mg/dL (1.8 mmol/L) did not reduce the incidence of new carotid plaques but produced significantly greater regression of carotid atherosclerosis than an LDL-C target of 90 to 110 mg/dL. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01252875. PMID: 32594766 [PubMed - as supplied by publisher]
Source: Circulation - June 28, 2020 Category: Cardiology Authors: Amarenco P, Hobeanu C, Labreuche J, Charles H, Giroud M, Meseguer E, Lavallée PC, Steg PG, Vicaut É, Bruckert E, Touboul PJ Tags: Circulation Source Type: research

Management of Hyperlipidemia After Stroke
AbstractPurpose of reviewHyperlipidemia is a key therapeutic target for stroke risk modification. The goal of this review is to highlight available treatment options and review their efficacy in the setting of general cardiovascular disease and after most subtypes of ischemic stroke and hemorrhagic stroke.Recent findingsStatins remain first-line in the management of hyperlipidemia to prevent stroke. In recent trials of patients with pre-existing atherosclerotic vascular disease, new agents, most notably PCSK9 inhibitors and ezetimibe, added additional stroke risk reduction when combined with statins.SummaryRisk of stroke c...
Source: Current Treatment Options in Cardiovascular Medicine - December 15, 2019 Category: Cardiology Source Type: research

Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS
ConclusionsAlthough most high-risk patients with T2D and CV disease were on lipid-lowering therapy, only 1:3 had LDL-C < 70 mg/dL and 1:6 had LDL-C < 55 mg/dL. Each 10 mg/dL higher LDL-C value was associated with a 5% and 6% higher 5-year incidence of MACE and CV death, respectively. (TECOS, NCT00790205).
Source: American Heart Journal - November 14, 2019 Category: Cardiology Source Type: research

Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial.
CONCLUSION: Elevated hs-CRP levels independently predicted a worse prognosis, regardless of LDL-C levels, suggesting that interventions against elevated inflammatory responses plus intensive lipid-lowering therapy and coronary revascularization are encouraging options for secondary prevention in ACS patients. TRIAL REGISTRATION: This trial is registered with the UMIN Clinical Trials Registry number UMIN000002742. Trial name: Proper level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome (HIJ-PROPER) URL: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr-view.cgi?recptno=R000003334. PMID: 3...
Source: Journal of Cardiology - November 3, 2019 Category: Cardiology Authors: Kawada-Watanabe E, Yamaguchi J, Sekiguchi H, Arashi H, Ogawa H, Hagiwara N Tags: J Cardiol Source Type: research